US drugs firm Pfizer has announced that it will be reducing its sales force by 20 per cent as part of the company's strategy to improve efficiency.
The move comes after the company announced an in-depth review of their operations in October of this year.
Jeffrey Kindler, Pfizer's chief executive officer, today insisted that the jobs cuts were necessary to making the firm more "agile and effective".
He went on say that the "relationship of our representatives with physicians and health care professionals is one of Pfizer's most important assets".
Pfizer are expected to announce the full results of the review in January and to reveal other strategies aimed at improving the world's largest research-based pharmaceuticals company.
Ian Read, president of Pfizer said: "It is incumbent upon us to look ahead and carefully assess our changing marketplace and all the factors affecting our outlook, so that we can align our organization to properly support our key products and customer needs."
He added that Pfizer would provide workers due to lose their jobs with "support services and benefits during their transitions".